Table 1.

Ideal inflammatory pathways to target

1. Involved in early disease

2. Associated with a biomarker that is readily measured in a non-invasive sample

3. Can be altered by a relatively simple pharmaceutical

4. Inhibition reduces inflammation without limiting ability to contain infection